Irwin Scher M.D., President & CEO, joined the company in 2005. Prior to joining Biosynexus, Dr. Scher served as a consultant to the CEO of Merck KGaA and as Vice President, Global Clinical Research & Development at Merck KGaA. Prior to this, he held the roles of Senior Vice President, Drug Development and Medical Affairs at Astra-Zeneca, and of Vice President Drug Development at Merck & Company Inc. Dr. Scher is a veteran of academic medicine, having spent fourteen years at the National Naval Medical Center, the Naval Medical Research Institute and the Uniformed Services University as the director of Rheumatology. Dr. Scher graduated from the New York State University at Albany New York, with a BS in Chemistry in 1962, followed by a degree in medicine from Albert Einstein College of Medicine. Dr. Scher has published 115 peer-reviewed papers, focused on B-cell activation and immunogenetics.

James Mond, M.D. Ph.D., Executive Vice President & Chief Scientific Officer, joined Biosynexus in 1999 with specific expertise in developing products for the prevention of bacterial infections. Prior to joining Biosynexus, Dr. Mond worked as a consultant to VSI. In this position he oversaw the development of the vaccine technology the company licensed to SmithKline Beecham. Dr. Mond was instrumental in ensuring the bacterial vaccine program with Smithkline Beecham moved forward, and his scientific insights led to new, patented vaccine technology. Dr. Mond received his M.D. and Ph.D. degrees from New York University Medical School. Dr. Mond worked in the prestigious laboratory of Immunology under Dr. Paul at the National Institute of Health. Dr. Mond is an acknowledged worldwide expert in Immunology with 156 publications in the most prestigious journals. He has acted as a consultant to the NIH, FDA, and pharmaceutical companies. Dr. Mond is a practicing board-certified Internist and Rheumatologist and is currently an adjunct Professor of medicine at the Uniformed Services University of the Health Sciences in Bethesda.


Dawn Litterio, Controller, is responsible for the day to day accounting functions for the company including accounts payable, payroll and financial statement preparation. Dawn has 18 years experience in the accounting industry, including 2 years in a local public accounting firm and 16 years in the private sector. Dawn joined Biosynexus after working most recently as the corporate controller for CRIIMI MAE Inc., a publicly traded Rockville, Maryland real estate investment trust. While at CRIIMI MAE, Dawn was responsible for all corporate accounting functions and SEC reporting on consolidated financial statements with over $130 million in revenue. Prior to that, Dawn worked as a senior consultant/auditor for a government contractor whose client base focused on work for the FDIC (Federal Deposit Insurance Corporation). Dawn has also held positions with Prudential Home Mortgage and Beers and Cutler, CPAs. Dawn holds a Bachelor of Business Administration in Accounting from Loyola University, New Orleans and a Master of Business Administration from the University of Maryland.